Human CD270 Protein, mFc Tag_天津卡梅德科技发展有限公司

>>

>>

>>

>

Human CD270 Protein, mFc Tag

Human CD270 Protein, mFc Tag

产品编号

KMP2283

别名

疱疹病毒入侵介质蛋白, Tumor Necrosis Factor Receptor Superfamily Member 14, CD270

规格

50ug
100ug
200ug

DATASHEET MSDS

立即询价加入询价列表大包装定制

产品介绍

Catalog Number	KMP2283
Alias	疱疹病毒入侵介质蛋白, Tumor Necrosis Factor Receptor Superfamily Member 14, CD270
Size	50ug, 100ug, 200ug
Product Description	The Human CD270 Protein(KMP2283) is produced in HEK293 Cells and the target gene encoding Pro37-Val202 is expressed with a mFc tag at the C-terminus.
Molecular Name	CD270
Product Introduction	CD270（HVEM）：TNF受体超家族成员，以跨膜形式参与多种免疫细胞间的信号传导。
Molecular Weight	17.52 kDa
Expression System	HEK293 Cells
Species	Human
Purity	>95%
Purification	Affinity Purification
Uniprot ID	Q92956
Storage Condition	Aliquot and store at -20℃ to -80℃. Avoid repeated freezing and thawing cycles.
Formulation	PBS, pH7.4
Shipping Condition	In general, the proteins are provided as lyophilized powder which are shipped at ambient temperature. They are shipped out in dry ice if supplied in liquid form.
Background	Herpesvirus entry mediator(HVEM) is a type I membrane protein in the TNF receptor superfamily, and it can both promote and inhibit T cell activity. HVEM is highly expressed on na-ve CD4+ T cells, CD8+ T memory cells, regulatory T cells, dendritic cells, monocytes, and neutrophils. It functions as a receptor for BTLA, CD160, LIGHT/TNFSF14, and Lymphotoxin-alpha. Ligation of HVEM by LIGHT triggers T cell, monocyte, and neutrophil activation and contributes to Th1 inflammation and cardiac allograft rejection. In contrast, HVEM binding to CD160 or BTLA suppresses T cell and dendritic cell activation and dampens intestinal inflammation. HVEM enhances the development of CD8+ T cell memory and Treg function. It is additionally expressed on intestinal epithelial cells, where its binding by intraepithelial lymphocyte(IEL) expressed CD160 promotes epitheilal integrity and host defense. The herpesvirus envelope glycoprotein gD, which binds HVEM to initiate membrane fusion, can antagonize both BTLA and LIGHT binding.
Endotoxin	<1.0 EU/ug determined by the LAL method
Product Declaration	该产品仅供科研使用，不可直接用于人体或注射。

FAQ

蛋白溶解后浓度偏低，如何调整？

低速离心：12,000 rpm, 5分钟，去除不溶物。缓冲液置换：使用超滤离心管（如10 kDa截留分子量）浓缩。
如何提高重组蛋白的可溶性表达？

可优化表达条件（如降低诱导温度、调整IPTG浓度）、使用促溶标签（如SUMO、GST）、共表达分子伴侣，或尝试不同宿主系统（如哺乳动物细胞或昆虫细胞）以提高可溶性蛋白产量。

推荐产品

400-621-6806
18630936064（微信同号）
周一至周五 8:30-18:00
0